StemRIM (TYO:4599)

Market Cap	19.01B
Revenue (ttm)	n/a
Net Income (ttm)	-1.97B
Shares Out	62.14M
EPS (ttm)	-31.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,300
Average Volume	147,915
Open	305.00
Previous Close	304.00
Day's Range	301.00 - 308.00
52-Week Range	246.00 - 494.00
Beta	0.91
RSI	43.71
Earnings Date	Jun 11, 2025

About StemRIM

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. St...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 44
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4599